SAM
PTGX icon

SEB Asset Management’s Protagonist Therapeutics PTGX Stock Holding History

SEB Asset Management’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$25.7M Sell
209,963
-22,453
-10% -$2.35M 0.1% 185
2026
Q1 		$24.5M Buy
+232,416
New +$20.6M 0.1% 173

Other funds holding PTGX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

SEB Asset Management's PTGX Position: Q2 2026 in Review

SEB Asset Management reduced its Protagonist Therapeutics (PTGX) stake by 9.7% in Q2 2026, selling an estimated $2.35M and leaving 209,963 shares worth $25.7M. The position accounts for 0.1% of the portfolio, ranked #185.

SEB Asset Management first reported a position in PTGX in Q1 2026 and has held it in 2 quarters since. 316 funds tracked by Wall St. Rank hold PTGX as of Q2 2026.

  • SEB Asset Management held 209,963 shares of Protagonist Therapeutics worth $25.7M as of Q2 2026.
  • SEB Asset Management sold 22,453 Protagonist Therapeutics shares in Q2 2026, an estimated $2.35M.
  • Protagonist Therapeutics made up 0.1% of SEB Asset Management's portfolio in Q2 2026, its #185 holding.
  • SEB Asset Management first reported a position in Protagonist Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 316 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q2 2026.

Based on SEB Asset Management's 13F filing for Q2 2026, filed 4 Aug 2026.